Mutant Native Outer Membrane Vesicles Combined with a Serogroup A Polysaccharide Conjugate Vaccine for Prevention of Meningococcal Epidemics in Africa

Impact of the Serogroup A Meningococcal Conjugate Vaccine, MenAfriVac, on Carriage and Herd Immunity

(2012) Paul A. Kristiansen, Fabien Diomandé, Absatou Ky Ba, Idrissa Sanou, Abdoul–Salam Ouédraogo, Rasmata Ouédraogo, Lassana Sangaré, Denis Kandolo, Flavien Aké, Inger Marie Saga, Thomas A. Clark, Lara Misegades, Stacey W. Martin, Jennifer Dolan Thomas, Sylvestre R. Tiendrebeogo, Musa Hassan-King, Mamoudou H. Djingarey, Nancy E. Messonnier, Marie-Pierre Préziosi, F. Marc LaForce, Dominique A. Caugant   CLINICAL INFECTIOUS DISEASES

Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial

(2012) Peter C Richmond et al.   LANCET INFECTIOUS DISEASES

Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data

(2012) Ryan T Novak et al.   LANCET INFECTIOUS DISEASES

Commentary

(2012) Dan M. Granoff   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Molecular Characterization of Invasive Meningococcal Isolates from Countries in the African Meningitis Belt before Introduction of a Serogroup A Conjugate Vaccine

(2012) Dominique A. Caugant et al.   PLoS One

An Outer Membrane Vesicle Vaccine for Prevention of Serogroup A and W-135 Meningococcal Disease in the African Meningitis Belt

(2012) G. Norheim et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: Results of a randomised, controlled, dose-escalation phase 1 trial

(2012) P.C. Richmond et al.   VACCINE

Characterization of size, structure and purity of serogroup X Neisseria meningitidis polysaccharide, and development of an assay for quantification of human antibodies

(2012) Ouli Xie et al.   VACCINE

Effectively introducing a new meningococcal A conjugate vaccine in Africa: The Burkina Faso experience

(2012) Mamoudou H. Djingarey et al.   VACCINE

The Effect of Human Factor H on Immunogenicity of Meningococcal Native Outer Membrane Vesicle Vaccines with Over-Expressed Factor H Binding Protein

(2012) Peter T. Beernink et al.   PLoS Pathogens

BIGSdb: Scalable analysis of bacterial genome variation at the population level

(2011) Keith A Jolley et al.   BMC BIOINFORMATICS

A Critical Threshold of Meningococcal Factor H Binding Protein Expression Is Required for Increased Breadth of Protective Antibodies Elicited by Native Outer Membrane Vesicle Vaccines

(2011) Oliver Koeberling et al.   Clinical and Vaccine Immunology

Meningococcal Group C and W135 Immunological Hyporesponsiveness in African Toddlers

(2011) Helen Findlow et al.   Clinical and Vaccine Immunology

Product Development Partnerships Hit Their Stride: Lessons From Developing A Meningitis Vaccine For Africa

(2011) David M. Bishai et al.   HEALTH AFFAIRS

Meningococcal glycoconjugate vaccines

(2011) Roberto Gasparini et al.   Human vaccines & immunotherapeutics

Complement-Mediated Bactericidal Activity of Anti-Factor H Binding Protein Monoclonal Antibodies against the Meningococcus Relies upon Blocking Factor H Binding

(2011) Serena Giuntini et al.   INFECTION AND IMMUNITY

A Meningococcal Factor H Binding Protein Mutant That Eliminates Factor H Binding Enhances Protective Antibody Responses to Vaccination

(2011) P. T. Beernink et al.   JOURNAL OF IMMUNOLOGY

Immunogenicity and Safety of a Meningococcal A Conjugate Vaccine in Africans

(2011) Samba O. Sow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epidemiology, Molecular Characterization and Antibiotic Resistance of Neisseria meningitidis from Patients ≤15 Years in Manhiça, Rural Mozambique

(2011) Ana Belén Ibarz-Pavón et al.   PLoS One

Rational Design of a Meningococcal Antigen Inducing Broad Protective Immunity

(2011) M. Scarselli et al.   Science Translational Medicine

Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys

(2011) Oliver Koeberling et al.   VACCINE

Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and Neisserial heparin binding antigen

(2011) David M. Vu et al.   VACCINE

A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression

(2011) P.B. Keiser et al.   VACCINE

The changing and dynamic epidemiology of meningococcal disease

(2011) Scott A. Halperin et al.   VACCINE

Meningococcal Factor H Binding Proteins in Epidemic Strains from Africa: Implications for Vaccine Development

(2011) Rolando Pajon et al.   PLoS Neglected Tropical Diseases

Epidemiological Profile of Meningococcal Disease in the United States

(2010) Lee H. Harrison   CLINICAL INFECTIOUS DISEASES

Multicenter, Open‐Label, Randomized Phase II Controlled Trial of an Investigational Recombinant Meningococcal Serogroup B Vaccine With and Without Outer Membrane Vesicles, Administered in Infancy

(2010) Jamie Findlow et al.   CLINICAL INFECTIOUS DISEASES

Innate immune function of the neisserial porins and the relationship to vaccine adjuvant activity

(2010) Lee M Wetzler   Future Microbiology

Characterization of Diverse Subvariants of the Meningococcal Factor H (fH) Binding Protein for Their Ability To Bind fH, To Mediate Serum Resistance, and To Induce Bactericidal Antibodies

(2010) Kate L. Seib et al.   INFECTION AND IMMUNITY

Meningococcal group A, C, Y and W-135 conjugate vaccine

(2010) Lee H. Harrison et al.   NATURE REVIEWS DRUG DISCOVERY

Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine

(2010) Wendell D. Zollinger et al.   VACCINE

Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease

(2010) Han-Qing Jiang et al.   VACCINE

Glycoconjugate vaccines and immune interference: A review

(2010) Ron Dagan et al.   VACCINE

Distribution of factor H binding protein beyond serogroup B: Variation among five serogroups of invasive Neisseria meningitidis in South Africa

(2010) Kedibone M. Mothibeli et al.   VACCINE

Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1

(2010) Brunella Brunelli et al.   VACCINE

The Meningococcal Vaccine Candidate Neisserial Surface Protein A (NspA) Binds to Factor H and Enhances Meningococcal Resistance to Complement

(2010) Lisa A. Lewis et al.   PLoS Pathogens

Changes inNeisseria meningitidisDisease Epidemiology in the United States, 1998–2007: Implications for Prevention of Meningococcal Disease

(2009) Amanda C. Cohn et al.   CLINICAL INFECTIOUS DISEASES

Sequence Diversity of the Factor H Binding Protein Vaccine Candidate in Epidemiologically Relevant Strains of Serogroup BNeisseria meningitidis

(2009) Ellen Murphy et al.   JOURNAL OF INFECTIOUS DISEASES

Meningococcal Factor H–Binding Protein Variants Expressed by Epidemic Capsular Group A, W‐135, and X Strains from Africa

(2009) P. T. Beernink et al.   JOURNAL OF INFECTIOUS DISEASES

A region of the N-terminal domain of meningococcal factor H-binding protein that elicits bactericidal antibody across antigenic variant groups

(2009) Peter T. Beernink et al.   MOLECULAR IMMUNOLOGY

Immunogenicity and Immune Memory of a Nonadjuvanted Quadrivalent Meningococcal Glycoconjugate Vaccine in Infants

(2009) Kirsten P. Perrett et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

A Randomized Trial to Determine the Tolerability and Immunogenicity of a Quadrivalent Meningococcal Glycoconjugate Vaccine in Healthy Adolescents

(2009) Lisa A. Jackson et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: A persistent problem with an imminent solution

(2009) F. Marc LaForce et al.   VACCINE

Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages

(2009) Michael Bröker et al.   VACCINE

Global epidemiology of meningococcal disease

(2009) Lee H. Harrison et al.   VACCINE

Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates

(2009) Rolando Pajon et al.   VACCINE

Meningococcal Outer Membrane Vesicle Vaccines Derived from Mutant Strains Engineered To Express Factor H Binding Proteins from Antigenic Variant Groups 1 and 2

(2008) O. Koeberling et al.   Clinical and Vaccine Immunology

Neisseria meningitidis PorB, a Toll-Like Receptor 2 Ligand, Improves the Capacity of Francisella tularensis Lipopolysaccharide To Protect Mice against Experimental Tularemia

(2008) D. Chiavolini et al.   Clinical and Vaccine Immunology

Bactericidal Antibody Responses Induced by Meningococcal Recombinant Chimeric Factor H-Binding Protein Vaccines

(2008) P. T. Beernink et al.   INFECTION AND IMMUNITY

Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years

(2008) Y. Galloway et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

A Multivalent Conjugate Vaccine for Prevention of Meningococcal Disease in Infants

(2008) Lee H. Harrison   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Bactericidal Antibody Responses Elicited by a Meningococcal Outer Membrane Vesicle Vaccine with Overexpressed Factor H–Binding Protein and Genetically Attenuated Endotoxin

(2008) Oliver Koeberling et al.   JOURNAL OF INFECTIOUS DISEASES

Factor H and Neisserial pathogenesis

(2008) Jo Anne Welsch et al.   VACCINE

Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa

(2008) Che-Hung Lee et al.   VACCINE